Rimegepant
![]() | |
Clinical data | |
---|---|
Synonyms | BHV-3000, BMS-927711 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C28H28F2N6O3 |
Molar mass | 534.57 g·mol−1 |
3D model (JSmol) | |
| |
|
Rimegepant (BHV-3000; formerly BMS-927711) is an investigational drug candidate for the treatment of migraine. Originally discovered at Bristol-Myers Squibb,[1] it is currently under development by Biohaven Pharmaceuticals.[2]
Mechanism of action
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.[3]
References
- ↑ "Drug Profile: Rimegepant". Adis Insight.
- ↑ "Rimegepant (BHV-3000) – for acute treatment of Migraine". Biohaven Pharmaceuticals.
- ↑ Diener, Hans-Christoph; Charles, Andrew; Goadsby, Peter J; Holle, Dagny (2015). "New therapeutic approaches for the prevention and treatment of migraine". The Lancet Neurology. 14 (10): 1010. doi:10.1016/S1474-4422(15)00198-2. PMID 26376968.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.